Oncology Medical News about mucoepidermoid carcinoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Clinicopathological significance of the CRTC3–MAML2 fusion transcript in mucoepidermoid carcinoma
Modern Pathology, 09/17/09

Nakayama T et al. – Mucoepidermoid carcinomas possessing CRTC3–MAML2 fusion may be associated with favorable clinicopathological features and patients may be younger than those with CRTC1–MAML2 fusion or those with no detectable gene fusion.

Methods

101 cases of mucoepidermoid carcinoma and 89 cases of non-mucoepidermoid carcinoma of the salivary gland were analyzed, and RNA was extracted from formalin-fixed, paraffin-embedded specimens
Clinicopathological data of the patients were obtained from their clinical records

Results

Of 101 cases of mucoepidermoid carcinoma, 34 (34%) and 6 (6%) were positive for CRTC1–MAML2 and CRTC3–MAML2 fusion transcripts
In the 89 cases of non-mucoepidermoid carcinoma, neither transcript was noted
In the former cases, CRTC1–MAML2 and CRTC3–MAML2 fusions were mutually exclusive
The other fusion, CRTC2–MAML2, was not detected
The clinicopathological features of CRTC1–MAML2-positive mucoepidermoid carcinomas indicated an indolent course
CRTC3–MAML2-positive mucoepidermoid carcinomas also had clinicopathologically favorable features; all cases showed a less advanced clinical stage, negative nodal metastasis, no high-grade tumor histology, and no recurrence or tumor-related death after surgical resection of the tumor
Patients with CRTC3–MAML2-positive tumors (mean 36 years of age) were significantly younger that those with the CRTC1–MAML2 fusion (55 years) and those with fusion-negative tumors (58 years)

<< Previous
The persistence of immunophenotypically normal residual bone...

Next >>
Update on the use of erythropoiesis-stimulating agents (ESAs) for...